Phylex BioSciences Publishes in Scientific Journal “Vaccine” Superior Immunogenicity Results in the Field of Nipah mRNA Vaccines
DEL MAR, California – July 23, 2025 – Phylex Biosciences has published in the peer-reviewed scientific journal Vaccine the positive results for its new mRNA nanoparticle vaccine candidate against the Nipah virus in an immunogenicity study conducted in collaboration with scientists of the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.
The Nipah virus, discovered in 1999, is a pathogen causing encephalitis and acute respiratory distress in humans with as much as a 50% fatality rate. The natural hosts of the virus are large fruit bats, which are geographically distributed across South and South-East Asia, Australia and the Pacific Islands, including some of the most densely populated regions on the planet.
Over the past two decades, the Nipah virus has spilled over into humans almost annually in Bangladesh and India and has also caused outbreaks in Malaysia, the Philippines and Singapore. To date, no approved vaccine or therapeutic exists against the Nipah virus.
Phylex has now published (https://authors.elsevier.com/a/1lTvj,60n7vpAM) the results of immunogenicity studies of its mRNA nanoparticle vaccine candidate against the Nipah virus in mice. The article, co-authored with scientists of the CDC, concludes that the vaccine elicits a robust neutralizing antibody response, with neutralizing titers markedly higher than with other mRNA Nipah vaccine designs, and efficient neutralizing even with a single dose.
The Phylex mRNA vaccine encodes for a nanoparticle displaying 60 copies of the antigen based upon the head domain of the G protein of the Nipah virus. In virus neutralization assays, neutralization titers of Phylex vaccine-elicited sera against Nipah virus were 3-fold the average titers of 14 individuals in Bangladesh who survived a Nipah virus infection. The Phylex vaccine elicited specific antibodies at an average concentration more than 60-fold as compared with the currently most advanced mRNA Nipah vaccine in clinical trials.
“We are grateful to our co-authors at the CDC for conducting assays to assess our vaccine against this difficult pathogen,” said Pascal Brandys, co-founder and CEO of Phylex Biosciences. “The results confirm the strong advantage of our mRNA vaccine encoding for a highly immunogenic nanoparticle, as compared with standard mRNA technology currently used in Nipah vaccine clinical trials.”
“Our vaccine combines the advantages of mRNA for speed of manufacturing and development with the efficacy of a nanoparticle after one dose”, Brandys continued. “This study confirms the urgency to pursue the clinical development of our vaccine candidate to initiate clinical trials with exposed individuals on a compassionate basis and to save lives as soon as possible”.
About Phylex BioSciences
Founded at the beginning of the COVID-19 pandemic by genomics pioneer Pascal Brandys and virologist Jens Herold, Phylex BioSciences is the first company to pursue the development of a mRNA nanoparticle vaccine against the Nipah virus.
Contact Media Relations:
+1-858-350-9100
media@phylexbio.com